文献速递白血病

人工智能加速流式细胞术对可测量残留B淋巴母细胞白血病的判读

Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.
PubMed 文献 · Blood Adv · 2026-01-01

该研究开发了一种基于云的人工智能增强流程,用于加速和简化B细胞急性淋巴细胞白血病(B-ALL)的可测量残留病(MRD)流式细胞术分析。研究处理了171例MRD阳性和89例MRD阴性的B-ALL病例,结果显示AI增强后的文件手动分析平均仅需1.01分钟,与常规分析相比阳性一致性和阴性一致性均为100%,定量相关性优秀(R2=0.92),且不损害检测性能。

要点

  • 深度神经网络细胞分类器识别正常造血亚群,宏平均F1分数为0.86。
  • AI异常度量区分B-ALL与良性单核细胞(AUC=0.98)或B淋巴样细胞(AUC=0.94)。

核心结论

  • 基于云的AI增强方案可加速B-ALL MRD识别而不损害检测性能,并有可能促进更多临床实验室开展B-ALL MRD分析。

研究设计与样本

  • 研究纳入171例B-ALL MRD阳性病例和89例MRD阴性病例的原始流式细胞术文件,使用31例专家设门的阴性对照训练AI流程。

主要发现

  • 深度神经网络细胞分类器自动识别正常造血亚群,宏平均F1分数为0.86。
  • AI异常度量区分B-ALL与良性单核细胞的AUC为0.98,区分B-ALL与B淋巴样细胞的AUC为0.94。
  • AI增强文件的手动分析平均仅需1.01分钟(标准差±0.57),与常规分析相比,对MRD≥0.01%的阳性一致性为100%,阴性一致性为100%,定量相关性优秀(R2=0.92)。

关键数值与推荐

  • MRD阳性一致性评估阈值:MRD≥0.01%时阳性一致性为100%。
  • AI细胞分类器宏平均F1分数为0.86。
  • AI异常度量区分B-ALL与良性单核细胞的AUC为0.98,与B淋巴样细胞的AUC为0.94。
  • AI增强文件手动分析平均时间1.01分钟(标准差±0.57)。
  • 定量相关性R2=0.92。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) assessment by flow cytometry (FC) plays an essential role in prognosis and therapy escalation of B-cell acute lymphoblastic leukemia (B-ALL). However, the high degree of expertise and manual analysis time required limits the availability of this assay. To overcome this limitation, we developed a data-enhancing artificial intelligence (AI) pipeline that accelerates and simplifies MRD analysis. Unaltered FC files from 171 B-ALL MRD-positive and 89 MRD-negative cases were processed through an AI pipeline trained with 31 expert-gated negative controls. Cluster-informed downsampling reduced FC files from 1.2 million to 155 884 cells per case, on average, (87% cellularity reduction), whereas preserving small MRD populations (median, 100% retention for MRD of <1%) and allowing for true percentage MRD estimates using a correction factor. A deep neural network cell classifier automatically identified normal hematopoietic subsets (macro-averaged F1 score of 0.86); and an AI measure of anomaly discriminated B-ALL from benign mononuclear (area under the curve [AUC] of 0.98) or B-lymphoid cells (AUC of 0.94). Manual analysis of AI-enhanced files was completed in only 1.01 minutes per case, on average (standard deviation of ±0.57); with 100% positive agreement with conventional analysis (for MRD of ≥0.01%), 100% negative agreement, and excellent quantitative correlation (R2 = 0.92). Our cloud-based AI-enhancement solution accelerates B-ALL MRD identification without compromising test performance and has the potential of facilitating B-ALL MRD analysis by more clinical laboratories.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Seheult JN, Otteson GE, Timm MM, et al. Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry. Blood Adv. 2026. PMID: 40966417. doi:10.1182/bloodadvances.2025016126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。